Discontinued — last reported Q4 '25
Pneumovax23 — Sales
Merck & Co. Pneumovax23 — Sales decreased by 4.4% to $86.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 42.7%, from $150.00M to $86.00M. Over 4 years (FY 2021 to FY 2025), Pneumovax23 — Sales shows a downward trend with a -34.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand or successful retention of market share, while a decrease often signals product maturity, loss of market share to next-generation competitors, or shifts in immunization guidelines.
Detailed definition
This metric represents the total annual revenue generated from the sale of a specific pneumococcal polysaccharide vaccin...
Peer comparison
Comparable to revenue metrics for legacy vaccine products or mature pharmaceutical franchises at peer companies like Pfizer or GSK.
mrk_segment_pneumovax_23_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $304.00M | $555.00M | $584.00M | $346.00M | $306.00M | $262.00M | $290.00M | $192.00M | $184.00M | $280.00M | $168.00M | $122.00M | $118.00M | $136.00M | $150.00M | $81.00M | $76.00M | $90.00M | $86.00M |
| QoQ Change | — | +82.6% | +5.2% | -40.8% | -11.6% | -14.4% | +10.7% | -33.8% | -4.2% | +52.2% | -40.0% | -27.4% | -3.3% | +15.3% | +10.3% | -46.0% | -6.2% | +18.4% | -4.4% |
| YoY Change | — | — | — | — | +0.7% | -52.8% | -50.3% | -44.5% | -39.9% | +6.9% | -42.1% | -36.5% | -35.9% | -51.4% | -10.7% | -33.6% | -35.6% | -33.8% | -42.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pneumovax23 — sales?
- Merck & Co. (MRK) reported pneumovax23 — sales of $86.00M in Q4 2025.
- How has Merck & Co.'s pneumovax23 — sales changed year-over-year?
- Merck & Co.'s pneumovax23 — sales decreased by 42.7% year-over-year, from $150.00M to $86.00M.
- What is the long-term trend for Merck & Co.'s pneumovax23 — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s pneumovax23 — sales has grown at a -34.3% compound annual growth rate (CAGR), from $1.79B to $333.00M.
- What does pneumovax23 — sales mean?
- The total annual revenue generated from the sales of the Pneumovax 23 vaccine product line.